Dose ranging study of monalizumab (IPH2201) in patients with gynecologic malignancies: A trial of the Canadian Cancer Trials Group (CCTG): IND221. (December 2016) - Tinker, A.; Hirte, H.; Provencher, D.; Butler, M.; Ritter, H.; Tu, D.; Paralejas, P.; Grenier, N.; Hahn, S.; Ramsahai, J.; Seymour, L.